Drug intelligence / Profile preview

TSHR+CD19 CAR-T cells

Development stage: Unknown
Lead developer: Zhejiang University
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

**TSHR+CD19 CAR-T cells** is an investigational dual-target chimeric antigen receptor T-cell therapy for relapsed or refractory thyroid cancer. The treatment uses engineered T cells directed against thyroid-stimulating hormone receptor and B-lymphocyte antigen CD19, with intended CAR-mediated activation and cytotoxic elimination of target-antigen-expressing cells. A ChiCTR-registered study, ChiCTR1900022607, evaluated its safety and efficacy in relapsed or refractory thyroid cancer; a published case report described partial remission after treatment in a patient with refractory thyroid cancer. Innovative Cellular Therapeutics manufactured and supplied the reported product. ([chictr.org.cn](https://www.chictr.org.cn/showproj.html?proj=38183))

Other names: (TSHR+CD19) CART cellsTSHR + CD19 CAR-TTSHR+CD19 CAR-T cellsTSHR+CD19 CART cells

Targets

CD19 (B lymphocyte antigen CD19)TSHR (Thyroid-stimulating hormone receptor)

Beyond the preview

Go deeper on TSHR+CD19 CAR-T cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TSHR+CD19 CAR-T cells.

Explore the full profile